Bank of New York Mellon Corp Sells 42,389 Shares of Becton Dickinson and Co (BDX)

Bank of New York Mellon Corp trimmed its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,753,417 shares of the medical instruments supplier’s stock after selling 42,389 shares during the period. Bank of New York Mellon Corp owned 1.03% of Becton Dickinson and worth $659,610,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mainstay Capital Management LLC ADV grew its holdings in Becton Dickinson and by 8,211.2% during the second quarter. Mainstay Capital Management LLC ADV now owns 97,989 shares of the medical instruments supplier’s stock valued at $611,000 after purchasing an additional 96,810 shares during the period. Public Employees Retirement System of Ohio grew its holdings in Becton Dickinson and by 1.2% during the second quarter. Public Employees Retirement System of Ohio now owns 239,650 shares of the medical instruments supplier’s stock valued at $57,411,000 after purchasing an additional 2,931 shares during the period. Waverton Investment Management Ltd grew its holdings in Becton Dickinson and by 1.4% during the second quarter. Waverton Investment Management Ltd now owns 456,863 shares of the medical instruments supplier’s stock valued at $109,446,000 after purchasing an additional 6,351 shares during the period. Fundsmith Equity Fund L.P. acquired a new position in Becton Dickinson and during the second quarter valued at approximately $894,775,000. Finally, SRS Capital Advisors Inc. grew its holdings in Becton Dickinson and by 20.6% during the second quarter. SRS Capital Advisors Inc. now owns 1,782 shares of the medical instruments supplier’s stock valued at $427,000 after purchasing an additional 305 shares during the period. 92.40% of the stock is owned by institutional investors and hedge funds.

A number of research analysts recently issued reports on BDX shares. Morgan Stanley boosted their price objective on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Wells Fargo & Co boosted their price objective on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Royal Bank of Canada restated a “hold” rating and set a $248.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. KeyCorp restated a “buy” rating and set a $264.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, Barclays started coverage on shares of Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $255.40.



Becton Dickinson and stock opened at $229.00 on Monday. The company has a market capitalization of $61.27 billion, a PE ratio of 21.93, a P/E/G ratio of 1.36 and a beta of 1.11. Becton Dickinson and Co has a twelve month low of $203.99 and a twelve month high of $265.87. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.86 by $0.05. The company had revenue of $4.28 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The business’s quarterly revenue was up 41.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.46 earnings per share. As a group, equities research analysts predict that Becton Dickinson and Co will post 11.01 EPS for the current fiscal year.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Story: Trading Strategy Examples and Plans

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply